Comparative Pharmacology
Head-to-head clinical analysis: MATULANE versus PURINETHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MATULANE versus PURINETHOL.
MATULANE vs PURINETHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.
Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.
200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.
1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.
None Documented
None Documented
Terminal elimination half-life is approximately 7-10 hours (range 5-15 hours) in adults; context: prolonged in hepatic or renal impairment.
The terminal elimination half-life of mercaptopurine is approximately 1.5 hours. However, the active metabolite 6-thioguanine nucleotides have a half-life of 5-7 days, correlating with pharmacological effects.
Primarily renal (approximately 50-60% as unchanged drug and metabolites) and fecal (approximately 10-20%); minor biliary excretion.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 50% of elimination. Biliary excretion contributes to a minor extent (<10%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent